Harmony Biosciences Holdings, Inc. (HRMY) Income Statement

The sequential build indicates the WAKIX franchise is still expanding in absolute terms, but the deceleration in year-over-year growth suggests the early launch-phase patient additions are being overtaken by a slower maintenance-driven base. Investors should evaluate whether persistence and prescriber breadth can sustain growth without a materially larger contribution from new indications.

The gross margin trend is consistent with rising rebate or channel costs needed to defend formulary access, which may indicate that pricing power is weaker than the historical peak margins implied. Because royalties to Bioprojet are a structural variable cost, further compression would likely require explicit disclosure to confirm whether the decline is cyclical or permanent.

The pattern suggests that step-ups in R&D spending for label expansion are absorbing gains in gross profit, so the scaling benefit of the commercial infrastructure is not yet visible on a steady basis. Investors should monitor whether R&D intensity normalizes, which would be needed to confirm a durable expansionary margin profile.